Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Analysis of Medical Use and Costs of Liver Transplant Patients Using National Patients Sample Data

환자표본자료를 이용한 간이식 환자의 의료이용 특성 및 의료비용 분석

  • Received : 2018.01.22
  • Accepted : 2018.02.18
  • Published : 2018.03.02
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Patients experience significant differences in aspects of mortality, quality of life, and costs between during the year of receiving liver transplant (LT) and the subsequent years (post-LT). This study aimed to estimate the medical utilization and cost of LT for patients compared to post-LT patients by using a recent National Patient Sample (NPS) data provided by the Korean Health Insurance Review and Assessment Service (HIRA). Methods: This study used a subset of the 2015 HIRA-NPS. Patient claims data that included Z944 (Korean Standard Classification of Diseases code for LT status) were selected. Within the selected data, LT patients were identified based on whether the national health insurance number code of Q80 (procedure code for LT surgery) was included, and they were compared to post-LT patients. Results: In the analysis, 330 patients were included. The average cost per patient was $90,066{\pm}36,959$ thousand KRW and $10,557{\pm}9,668$ thousand KRW for LT and post-LT patients, respectively. Especially, LT patients' costs for injection/procedure, surgery/treatment, and examination were higher than other costs, being $35,983{\pm}18,115$ thousand KRW, $28,246{\pm}9,408$ thousand KRW, and $12,131{\pm}6,604$ thousand KRW, respectively. For inpatients, the average number of hospitalized days was $63.5{\pm}66.0$ days for LT patients and $22.3{\pm}35.1$ days for post-LT patients. Conclusion: Compared to post-LT patients, LT patients had higher costs, especially for injection/procedure, surgery/treatment, and examination. Additionally, the LT group had longer hospitalization duration and higher costs for their hospital admission, whereas they did not show a significant difference in number of visits and medical costs for outpatient-care.

Keywords

References

  1. The Korean Association for the Study of the Liver. White Paper on Liver Diseases in Korea. 2013. Available from http://www.kasl.org/bbs/index.html?code=ency&category=&gubun=&idx=&page=1&number=55&mode=view&order=&sort=&keyfield=&key=. Accessed January 16, 2018.
  2. Kim MS. Modification of Emergency Status in Deceased Donor Liver Allocation: Evidence for Korean Model of End-stage Liver Disease (MELD) System. J Korean Soc Transplant 2016; 30(2):51-8. https://doi.org/10.4285/jkstn.2016.30.2.51
  3. Lim Y-S. Acute liver failure in Korea: etiology, prognosis and treatment. Korean J Hepatol 2010; 16(1):5-18.
  4. Lee HJ. Liver Transplantation in Liver Cirrhosis. CMH 2006;12(20): 85-9.
  5. Korean Network for Organ Sharing. Guidance on organ transplant management in 2016. Available from https://www.konos.go.kr/konosis/common/bizlogic.jsp. Accessed January 16, 2018.
  6. Korean Network for Organ Sharing. Statistics of Organ Transplantation Cases. Available from https://www.konos.go.kr/konosis/sub4/sub-04_03_01_pop.jsp. Accessed January 16, 2018.
  7. The Korean Association for the Study of the Liver. Clinical Guideline for liver Cirrhosis: Ascites and other complications. 2017. Available from http://www.kasl.org/bbs/index.html?code=guide&cate-gory=&gubun=&idx=&page=1&number=3358&mode=view &order=&sort=&keyfield=&key=. Accessed on January 16, 2018.
  8. Healthcare Bigdata Hub. Available from http://opendata.hira.or.kr/home.do. Accessed January 16, 2018.
  9. Chhatwal J, Kanwal F, Roberts MS, et al. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med 2015; 162(6):397-406. https://doi.org/10.7326/M14-1336
  10. Cure S, Guerra I, Dusheiko G. Cost-effectiveness of sofosbuvir for the treatment of chronic hepatitis C-infected patients. J Viral Hepat 2015; 22(11):882-9. https://doi.org/10.1111/jvh.12409
  11. Leleu H, Blachier M, Rosa I. Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C. J Viral Hepat 2015; 22(4):376-83. https://doi.org/10.1111/jvh.12311
  12. Liu S, Watcha D, Holodniy M, et al. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis. Ann Intern Med 2014;161(8):546-53. https://doi.org/10.7326/M14-0602
  13. Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 2015;162(6):407-19. https://doi.org/10.7326/M14-1152
  14. Petta S, Cabibbo G, Enea M, et al. Cost-effectiveness of sofosbuvirbased triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2014;59(5):1692-705. https://doi.org/10.1002/hep.27010
  15. Pfeil AM, Reich O, Guerra IM, et al. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in swiss patients with chronic hepatitis C. PLoS One 2015;10(5):e0126984. https://doi.org/10.1371/journal.pone.0126984
  16. Saab S, Gordon SC, Park H, et al. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 2014;40(6):657-75. https://doi.org/10.1111/apt.12871
  17. Ke W, Zhang C, Liu L, et al. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China. Hepatol Int 2016;10(6):924-36. https://doi.org/10.1007/s12072-016-9741-6
  18. Wu B, Li T, Chen H, et al. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis. Value Health 2010; 13(5):592-600. https://doi.org/10.1111/j.1524-4733.2010.00733.x
  19. Zhang C, Ke W, Gao Y, et al. Cost-effectiveness analysis of antiviral therapies for hepatitis B e antigen-positive chronic hepatitis B patients in China. Clin Drug Investig 2015;35(3):197-209. https://doi.org/10.1007/s40261-015-0273-y
  20. San Miguel R, Gimeno-Ballester V, Blazquez A, et al. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut 2015;64(8):1277-88. https://doi.org/10.1136/gutjnl-2014-307772
  21. Samsung Medical Center-Organ transplantation Center. FAQ-Cost for organ transplantation. Available from http://www.samsunghospital.com/dept/main/index.do?DP_CODE=OTC&MENU_ID= 007085160. Accessed January 16, 2018.
  22. Asan Medical Center-Organ Transplantation Center. Organ transplant procedure. Available from http://organ.amc.seoul.kr/asan/depts/organ/K/content.do?menuId=1610. Accessed January 16, 2018.
  23. Cruz RJ, Ranganathan S, Mazariegos G, et al. Analysis of national and single-center incidence and survival after liver transplantation for hepatoblastoma: New trends and future opportunities. Surgery 2013; 153(2):150-9. https://doi.org/10.1016/j.surg.2012.11.006
  24. Jain A, Reyes J, Kashyap R, et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000;232(4):490-500. https://doi.org/10.1097/00000658-200010000-00004
  25. Levy AR, Kowdley KV, Iloeje U, et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health 2008;11(3):527-38. https://doi.org/10.1111/j.1524-4733.2007.00297.x
  26. Sakata H, Tamura S, Sugawara Y, et al. Cost analysis of adult-adult living donor liver transplantation in Tokyo University Hospital. J Hepatobiliary Pancreat Sci 2011;18(2):184-9. https://doi.org/10.1007/s00534-010-0326-9
  27. Serper M, Bittermann T, Rossi M, et al. Functional status, healthcare utilization, and the costs of liver transplantation. Am J Transplant 2017. doi: 10.1111/ajt.14576. [Epub ahead of print]
  28. Thongsawat S, Piratvisuth T, Pramoolsinsap C, et al. Resource Utilization and Direct Medical Costs of Chronic Hepatitis C in Thailand: A Heavy but Manageable Economic Burden. Value in Health Regional Issues 2014;3:12-18. https://doi.org/10.1016/j.vhri.2013.09.002
  29. Kitazawa T, Matsumoto K, Fujita S, et al. Cost Analysis of Transplantation in Japan, Performed With the Use of the National Database. Transplant Proc 2017;49(1):4-9. https://doi.org/10.1016/j.transproceed.2016.10.007
  30. Lee H, Shin U, Lee C, et al. Medical Price Levels of OECD Countries: A Comparative Study: KMA Research Institute for Healthcare Policy, 2013. Available from http://www.dbpia.co.kr/Journal/ArticleDetail/NODE02467445. Accessed January 16, 2018.
  31. Abergel A, Rotily M, Branchoux S, et al. Chronic hepatitis C: Burden of disease and cost associated with hospitalisations in France in 2012 (The HEPC-LONE study). Clin Res Hepatol Gastroenterol 2016; 40(3):340-8. https://doi.org/10.1016/j.clinre.2015.08.006
  32. Kim Y, Shin S, Park J, et al. Costing methods in Healthcare: NECA, 2013. Available from https://www.neca.re.kr/lay1/bbs/S1T11C102/F/39/view.do?article_seq=5332&cpage=1&rows=10&condition=&keyword=&show=&cat=. Accessed January 16, 2018.
  33. Kim H-L, Park J-A, Sin J, et al. Analysis of Medical Use and Costs Related to the Management of Liver Cirrhosis Using National Patients Sample Data. Korean J Clin Pharm 2016;26(4):341-7.
  34. Shon C, Choi HY, Shim JJ, et al. The Economic Burden of Hepatitis A, B, and C in South Korea. Jpn J Infect Dis 2016;69(1):18-27. https://doi.org/10.7883/yoken.JJID.2014.499
  35. Chen GF, Wei L, Chen J, et al. Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data. PLoS One 2016; 11(6): e0155934. https://doi.org/10.1371/journal.pone.0155934
  36. Chhatwal J, He T, Hur C, et al. Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection are Cost Saving. Clin Gastroenterol Hepatol 2016;15(6):827-37. https://doi.org/10.1016/j.cgh.2016.09.015
  37. Virabhak S, Yasui K, Yamazaki K, et al. Cost-effectiveness of directacting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatmentnaive and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan. J Med Econ 2016:1-14.